Picard Medical's Upcoming Presentation at CSI Focus D-HF 2025
Picard Medical, Inc. is taking a significant step in advancing heart failure therapies. CEO Patrick NJ Schnegelsberg is set to attend the CSI Focus D-HF conference to showcase groundbreaking advancements in artificial heart technology. Known for creating the Emperor Total Artificial Heart, Picard Medical is at the forefront of innovation, bringing hope to end-stage heart failure patients.
Details of the Conference Presentation
During the conference held in Frankfurt, attendees will have the opportunity to hear from Schnegelsberg about the features and benefits of the Emperor Total Artificial Heart. This exceptional device is designed to be fully implantable, providing patients with a modern solution to heart failure.
Key Information About the Session
The presentation is scheduled for December 6, where Schnegelsberg will delve into key aspects of mechanical circulatory support, shedding light on the advancements that are transforming patient care. The session aims to address the evolving landscape of devices aimed at supporting heart failure.
About the CSI Focus D-HF Conference
The CSI Focus D-HF event represents a premier gathering of experts in heart failure management. This conference draws together leading cardiologists, engineers, and researchers, all focused on device-based therapies. Participants will engage with the latest device solutions, emphasizing advancements in implantable monitoring systems and telemedicine strategies.
Global Implications of Device Innovations
As heart failure remains a critical global health challenge, innovations like the Emperor Total Artificial Heart play a crucial role in addressing this crisis. The inclusion of various stakeholders at the conference underscores the importance of collaborative efforts in accelerating advancements and improving patient outcomes.
About Picard Medical and Its Commitment to Innovation
Picard Medical, a leader in heart technology, is the parent company of SynCardia Systems LLC. The latter is renowned for creating the SynCardia Total Artificial Heart, the first artificial heart approved by regulatory authorities in both the United States and Canada. More than 2,100 implants across 27 countries highlight the extensive use and study of this groundbreaking device.
The Future of Heart Technologies
As Picard Medical continues to innovate, the focus remains on improving the lives of patients with end-stage heart failure. The Emperor Total Artificial Heart stands as a testament to this mission, promising enhanced comfort and quality of life for those reliant on advanced medical devices.
Contact Information for Further Inquiries
For more information, Picard Medical encourages interested parties to reach out through their dedicated channels. For investor inquiries, Eric Ribner from LifeSci Advisors LLC can be contacted at eric@lifesciadvisors.com. General media inquiries can be directed to Brittany Lanza at blanza@syncardia.com.
Frequently Asked Questions
What is the significance of the Emperor Total Artificial Heart?
The Emperor Total Artificial Heart is a revolutionary device that serves patients experiencing end-stage heart failure by performing the functions of a human heart.
When will the presentation take place?
The presentation by Patrick NJ Schnegelsberg is scheduled for December 6 during the CSI Focus D-HF conference.
What topics will be addressed during the presentation?
The presentation will focus on durable mechanical circulatory support and the technological advancements behind the Emperor Total Artificial Heart.
Who should attend the CSI Focus D-HF conference?
The conference is tailored for cardiologists, engineers, and researchers interested in the latest device therapies for heart failure.
How can I learn more about Picard Medical?
For further details, you can visit their website at www.picardmedical.com or contact them directly for more information.
